EDN1 and systemic sclerosis: Despite the emerging concept of the use of molecular targets, such as endothelin-1, for the treatment of fibrosis in SSc, the clinical efficacy and safety profile of antifibrotic treatments including tyrosine kinase inhibitors such as imatinib await confirmation (45–48).